Table 6.
Cox survival analysis of predictors of local progression-free survival in 316 patients with 404 hepatocelluar carcinomas after radiofrequency ablation
| Characteristic |
Univariate |
Multivariate |
||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Sex | 1.073 | 0.691-1.667 | 0.753 | |||
| Age | 0.796 | 0.559-1.133 | 0.205 | |||
| Pathological grade | 2.258 | 1.506-3.385 | < 0.001 | |||
| Etiology of cirrhosis | 0.851 | 0.725-0.999 | 0.048 | |||
| Portal vein hypertension | 1.826 | 1.288-2.589 | 0.001 | |||
| Liver function enzyme | 1.082 | 0.740-1.583 | 0.684 | |||
| (AST/ALT) | ||||||
| Child-Pugh classification | 2.930 | 2.169-3.958 | < 0.001 | 2.416 | 1.713-3.409 | < 0.001 |
| Serum AFP | 1.425 | 1.010-2.011 | 0.044 | |||
| CEUS pre-RFA | 0.421 | 0.297-0.598 | < 0.001 | |||
| Number of tumors | 1.765 | 1.212-2.570 | 0.003 | 1.588 | 1.031-2.447 | 0.036 |
| Tumor size | 1.587 | 1.104-2.283 | 0.013 | |||
| Risky location | 1.442 | 1.013-2.054 | 0.042 | |||
| Type of RFA electrodes | 0.449 | 0.264-0.764 | 0.003 | |||
| Primary technical success | 1.772 | 0.877-3.583 | 0.111 | |||
| Number of RFA sessions | 1.574 | 1.201-2.061 | 0.001 | 1.550 | 1.183-2.033 | 0.002 |
HCC: Hepatocelluar carcinoma; HR: Hazard ratio; AFP: Alpha–fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CEUS: Contrast enhanced ultrasound; RFA: Radiofrequency ablation.